As the world grapples with the potential downsides of generative AI, a global group of healthcare researchers is warning of health perils that could emanate from well beyond clinical settings.
These findings highlight a need for more stringent and standardized reporting guidelines relative to incidental findings, authors of the new study suggested.
The new MRI contrast agent gadopiclenol, sold under the trade names Elucirem and Vueway by Bracco and Guerbet, uses 50% less gadolinium than current MRI agents.
The ACR Committee on Drugs and Contrast Media stated that exposure to the gadolinium-based contrast agent represents a “sufficiently low or possibly nonexistent” risk to patients.
These findings warrant serious consideration by physicians caring for pregnant women in the future, as the link between poor mental health and placental development remains “underappreciated.”
